Effect of 10mg Domperidone on Gastric Emptying of a High-fat Meal and Appetite Sensations in Healthy Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether domperidone was sufficient to accelerate gastric emptying of a high-fat solid meal and reduce satiety responses in a healthy adult population.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus |
Drug: Domperidone 10mg Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Single Blind (Subject) Primary Purpose: Basic Science |
| Official Title: | Does Domperidone, a D2-antagonist Alter Gastric Emptying Rates and Appetite Sensations in Healthy Adults? |
- Gastric emptying half time [ Time Frame: 6.5 Hours post ingestion ] [ Designated as safety issue: No ]Determination of Gastric emptying of a high-fat test meal measured by octanoic acid breath test after acute administration of 10mg domperidone
- Appetite sensations [ Time Frame: 6.5 hours post ingestion ] [ Designated as safety issue: No ]Determination of appetite sensations associated with ingestion of a high-fat test meal by visual analogue scale after acute administration of 10mg domperidone
| Enrollment: | 13 |
| Study Start Date: | February 2008 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
-
Drug: Domperidone 10mg
This study aims to investigate the effect of domperidone on gastric emptying and appetite sensations in healthy subjects. Domperidone is a dopamine 2 (D2) receptor antagonist with claims of gastrointestinal tract pro-kinetic activity. Accelerated gastric emptying (GE) may lead to reduced satiation, increased food intake and is associated with obesity and diabetes mellitus. It is hypothesized that domperidone will increase gastric emptying rate and reduce satiety responses to a high-fat meal.
The effect of acute oral administration of 10 mg domperidone on gastric emptying of a high-fat pancake test meal, and subjective appetite sensations by visual analogue scale will be measured for six hours postprandially in a randomized, placebo-controlled, single-blinded manner in 13 healthy subjects.
Eligibility| Ages Eligible for Study: | 10 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy adults aged 18-40 years
Exclusion Criteria:
- History of gastrointestinal-related conditions, diabetes mellitus or cardiovascular disease
Contacts and Locations| Ireland | |
| Department of Physical Education & Sport Sciences, University of Limerick | |
| Limerick, Ireland | |
| Principal Investigator: | Amir Shafat | University of Limerick |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Amir Shafat/Dr, University of Limerick |
| ClinicalTrials.gov Identifier: | NCT01347814 History of Changes |
| Other Study ID Numbers: | DompGastEmpt |
| Study First Received: | May 3, 2011 |
| Last Updated: | May 3, 2011 |
| Health Authority: | Ireland: Research Ethics Committee |
Keywords provided by University of Limerick:
|
Domperidone gastric emptying obesity diabetes mellitus Domperidone/pharmacology |
Pharmacologic Actions Physiological Effects of Drugs Gastrointestinal Agents Humans |
Additional relevant MeSH terms:
|
Pharmacologic Actions Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Gastrointestinal Agents Domperidone Physiological Effects of Drugs Therapeutic Uses |
Antiemetics Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents Dopamine Antagonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 21, 2013